Activation of both Syk and Lyn tyrosine kinases by treatment of intact erythrocytes
Treatment . | Tyrosine kinase activity, cpm . | |
---|---|---|
Anti-Syk IP . | Anti-Lyn IP . | |
None | 2 730 | 1 010 |
Pervanadate | 5 948 | 10 566 |
Pervanadate + PP2 | 5 725 | 910 |
Diamide | 6 215 | 10 416 |
Diamide + PP2 | 5 838 | 1 120 |
NEM | 6 063 | 10 275 |
NEM + PP2 | 5 790 | 930 |
Treatment . | Tyrosine kinase activity, cpm . | |
---|---|---|
Anti-Syk IP . | Anti-Lyn IP . | |
None | 2 730 | 1 010 |
Pervanadate | 5 948 | 10 566 |
Pervanadate + PP2 | 5 725 | 910 |
Diamide | 6 215 | 10 416 |
Diamide + PP2 | 5 838 | 1 120 |
NEM | 6 063 | 10 275 |
NEM + PP2 | 5 790 | 930 |
Human erythrocytes were incubated without or with 1 mmol/L pervanadate, 2 mmol/L diamide, and 1 mmol/L NEM in the absence or presence of 5 μM PP2. Isolated erythrocyte membranes were treated with extraction buffer, and extracted proteins were immunoprecipitated with anti-Syk or anti-Lyn antibodies. Tyrosine kinase activities of immunocomplexes were tested in vitro, as described in “Materials and methods.” Reported values represent the means for 4 separate experiments. SEMs were always less than 20%. IP indicates immunoprecipitate; NEM, N-ethylmaleimide.